Cancer Medications
Bioactivity-Mechanisms and Curativeness
So curing cancer, being the
reversal of the accelerated growth of
metabolism gone awry until or including the
biophagy
of the defective biologic, as observed can be accomplished with medications, carefully
chosen or pre-determined as having the requisite curativeness. Yet,
the latter,
however, proffers relative advantage.
Agreed,
curative drugs-cocktails have been found by trial and error,
and admittedly such finds are critical because, effectively, case
histories of cure by medications empower such treatments to be practised by other medical
professionals; even so, though, offering treatment on the promise of
potential for cure based on historical outcomes or even potential
for slowed-down growth also of historical observation are not
provisors of comfort to patients. More definitive assurances would
be more appropriate. Offer of treatments provoking confidence in
patients would be better grounded when based on a treatment
chemistry that is tenable.
In this regard then, the use of
predetermined-as-curative
medications would be better advisable. Computationally evaluating
"Bioactivity Mechanisms and Curativeness" of cancer
medications therefore proffer significant milestones towards the
cure of cancers. Such recognition motivates the Center to the end of
constructing bioactivity contexts of cancer medications of interest,
being cocktail designs on mostly drugs already approved by the
regional drug administration governmental agencies, which in the US
is the FDA.
Even so, the Center assigns more weight to collaborative work with
medical doctors, cancer researchers, and pharmacists all over the
world confronting the thorn of cancer in their patients and seek to
provide guidance on drugs-cocktails in mind for computational evaluation.
Particularly of interest are even some drugs which have to
determined to just reduce the rate of growth. By this route the
Center commits to at disposable of medical professional,
particularly oncologists, a facility capable of ascertaining the
bioactivity mechanism of cocktails, and in effect, avail a medical
professional basis for evaluating drugs-cocktails as possible cure
for specific cancers --by which is meant the cancer was no longer found
on subsequent examinations. Indisputably, for each submitted
cocktail, the Medications Bioactivity Mechanism and Curativeness
computed analytics remains the proprietary intellectual property of
the submitter professional,
Of course, the Center itself also works with its own medical
professional and research team to
design cocktails that it evaluates and makes available to
professional for procurement for prescription. However, this
Center-specific computational research extends at times to include
the sleuthing of the Defect Stressor. So then a validated Defect
Stressor so sleuthed empowers the team in designing the cocktail
prescription, the curativeness of which approach is based on such
knowledge of structure bio-condensation reactions mechanism as should
be.Systemic-Cancers Treatment
Guidance
Although, while cancer is localized or of localizable type,
treatments can include medication with drug --because the rate of
growth is slower than the rate of circulation of the blood that
carries the medication to the cancer location; that treatment is not
so appropriate when the cancer is systemic. Admittedly, drug
medications can be systemic yet in these cases when cancer is
systemic, the speed of delivery of the treatment to every possible
locale of the cancer cells is of the utmost, or so to say, directed
by the urgency of now.
Indeed, though cancers are often thought of as localized, cancer
affliction can be systemic such as when of the non-localizing types
such as blood cancers, because the blood circulation is systemic or
when the localizing cancer, metastasizes after expansive growth in
the human body and therefore transforms from a localized affliction
to a systemic affliction
Treatments for such cancers for cure are most effective when the
means of treatments also enable rapid systemic application. So
curing cancer, being the reversal of the accelerated growth of
metabolism gone awry until or including the
biophagy
of the Defect Stressor, as
observed can be accomplished with induced prolonged asphyxiation
leading to necrosis, or with forced denaturation of conformal
structure leading self exposure alert of immune cells destruction.
Given the options of use of Forensic Map and Ignition Hypothesis for
discovering the defective gene, derivative technology -- the
Non-Invasive Biologics-Biophagism Technologies; can be used and
be efficacious to the end of fastest delivery of treatment. Systemic
Cancer treatment specificity can be effected with the deployment as
the driver technology being either of the
Magnetoradiation class or of the
RadioDenaturation type.
Effectively the capacity for Forensic Maps and Hypothetic
Constructed Defect Stressor construction is of mission critical
import in treatments of systemic Cancers.
|
|
Genome Facility |
|
The Genome facility is the primary support of the
Cancer Treatment Guidance developing process. The facility is
the first tier support in the generating the Guidance. Effectively,
the facility enables the
computer-aided virtual biosynthesis of the genome of cells, and
as such of any cell in any part of a living organism,
unicellular or multi-cellular, prokaryote or eukaryote or archaea.
In essence the output of the
facility is the collection of all possible versions of the gene
that could form the genome of a specific cell.
The flexibility of the
Facility is unmatched in the sense that it incorporates the
chemical environment of the blood of the cancer patient as an
input into the process of constructing the genes. In that regard
the Facility brings to bear a level of ethnic specificity of the
cancer patient by considering the type of food consumed
regularly by the patient in course of characterizing the
Chemical environment of the blood and hence of the cell.
Though developed for use in the
study of cancer, the Genome Facility is particularly is
particularly advantageous in enabling the production of virtual
form of genes of any conceivable structure and geometry and can
obtain in real life in the context of the human body, whether or
such has been determined empirically in a laboratory. The
capability opens up the field of biology of all life's to the
study of biochemistry, Biophysics and metabolic chemical
reactions and kinetics, otherwise difficult to study.
This capacity derives from the
implementation of two foundational features: Chemical
Environment prevailing, and Bio-condensation -- an innovative
proprietary reaction class concept; that are significant in
lending both flexibility and expansiveness of
implementation of the virtual biosynthesis of the genome, of all
conceivable compositions of the genes
Contributions of Lifestyle, such as drinking, smoking and
illegal-drugs use, to the occurrence of cancer are
also reflected in the genome being captured through the
virtual-biosynthesis implementation. This is made possible
because of the capacity of further specialization of the key
feature of Chemical Environment with the substances
representation of the lifestyle of consideration, and so able to
perform epigenetics studies by simple variations of the chemical
environment
Other lifestyle matters such as feeding habits, living standard
and ventilation, exposure to toxic materials and substances, and
other metabolism impacting factors such as age-related matters
are also ready integrated into the genome context but in this
case through the easy of implementation of the Warburg
hypothesis in the design of the bio-condensation mechanism of
gene virtual biosynthesis. Generally all health-related
shortcomings that predicate the contexts of the Warburg
hypothesis is easily incorporated into the genome biosynthesis
using the mechanism representation of the hypothesis.
In fact, the facility is readily enabled to specialize the
obtaining genome variants to reflect endemicity again by
specializing the Chemical Environment to clusters of regionally
endemic food, and hence elicit the ethnicity-dependent cancer
incidences with endemic genome |
|